home > news > Company news
  • 2016-06-22 13:26:40
  • 5784

From the earlier regulatory successes of Adcetris® and Kadcyla® to the recent FDA approval of Blincyto®, to the current clinical successes of Opdivo® and Keytruda®, the industry is abuzz with excitement and new hope. The successes of antibody-drug conjugates, bispecific antibodies and immunotherapy drugs and combinations are opening new doors for biotech companies to discover and develop breakthrough remedies.

CHI’s 2nd Annual PEGS Korea brings these exciting developments to light by gathering the industry’s leading companies and institutions together to share their experiences from discovery to preclinical to clinical stage. Join us as we bring the event back to Seoul with even more case studies, more data, and more opportunities for collaborations.

PEGS Korea 2016 comprises of 2 exciting new tracks and a Short Course:

•      TRACK 1: Protein & Antibody Engineering - review emerging targets in cancer therapy and immunotherapy; discuss standardization and reproducibility challenges of antibodies; explore antibodies for viral infectious diseases; and showcase engineering and optimization strategies for bispecifics, ADCs, fusion proteins etc.

•      TRACK 2: Cancer Immunotherapy - current development and future outlook for immune checkpoint inhibitors; engineering and manufacturing challenges of adoptive T-cell therapies; as well as strategies and clinical updates on antibodies and bispecifics in cancer and inflammation.

•      SHORT COURSE: Troubleshooting and Engineering of Antibody Constructs


illiam R. Strohl, Ph.D., Vice President and Biologics Fellow, Janssen Research & Development, LLC

Patrick Baeuerle, Ph.D., Managing Director, MPM Capital

Dimiter Dimitrov, Ph.D., Senior Investigator, Cancer Inflammation Program, National Cancer Institute, NIH